Informational only — Not medical advice. Always consult a licensed healthcare provider.

Community data Updated 2 months ago
Available as: 20 mg · 20 mg vial

Indications & Uses

Simulect is an immunosuppressant agent used to prevent immediate transplant rejection in people who are receiving kidney transplants, in combination with other agents. It has been reported that some cases of lichen planus have been successfully treated with Simulect as an alternative therapy to ciclosporin. No short-term side effects have been reported.

Dosage Reference

Reference Information Only

Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.

Adults:

Dosage Adults: In adult patients, the recommended regimen is two doses of 20 mg each. The first 20 mg dose should be given within 2 hours prior to transplantation surgery. The recommended second 20 mg dose should be given 4 days after transplantation. The second dose should be withheld if complications such as severe hypersensitivity reactions to Basiliximab or graft loss occur.Pediatric: In pediatric patients weighing less than 35 kg, the recommended regimen is two doses of 10 mg each. In pediatric patients weighing 35 kg or more, the recommended regimen is two doses of 20 mg each. The first dose should be given within 2 hours prior to transplantation surgery. The recommended second dose should be given 4 days after transplantation. The second dose should be withheld if complications such as severe hypersensitivity reactions to Basiliximab or graft loss occur.

Side Effects

Serious side effect such as: Pain or burning when you urinate Easy bruising or bleeding, unusual weakness Tremors, shaking Fever, chills, body aches, flu symptoms, vomiting, diarrhea Trouble breathing Pale skin, feeling light-headed or short of breath, rapid heart rate, trouble

Cautions & Contraindications

Warnings & Precautions

Re-exposure to a subsequent course of therapy in patient who has previously received Simulect. Children, Pregnancy and lactation.

Contraindications

Known hypersensitivity to basiliximab or any component of the formulation

Last updated: 20 Aug 2026